S&P 500   4,073.51 (-0.16%)
DOW   34,344.96 (-0.71%)
QQQ   293.45 (+0.03%)
AAPL   148.12 (+0.06%)
MSFT   254.27 (-0.34%)
META   120.35 (+1.91%)
GOOGL   101.19 (+0.20%)
AMZN   95.59 (-0.98%)
TSLA   194.76 (+0.03%)
NVDA   172.08 (+1.68%)
NIO   12.28 (-3.91%)
BABA   86.13 (-1.63%)
AMD   77.10 (-0.68%)
T   19.10 (-0.93%)
MU   55.40 (-3.90%)
CGC   3.71 (+2.49%)
F   14.03 (+0.94%)
GE   85.44 (-0.62%)
DIS   97.78 (-0.09%)
AMC   8.57 (+18.53%)
PYPL   78.46 (+0.06%)
PFE   50.78 (+1.30%)
NFLX   316.52 (+3.60%)
S&P 500   4,073.51 (-0.16%)
DOW   34,344.96 (-0.71%)
QQQ   293.45 (+0.03%)
AAPL   148.12 (+0.06%)
MSFT   254.27 (-0.34%)
META   120.35 (+1.91%)
GOOGL   101.19 (+0.20%)
AMZN   95.59 (-0.98%)
TSLA   194.76 (+0.03%)
NVDA   172.08 (+1.68%)
NIO   12.28 (-3.91%)
BABA   86.13 (-1.63%)
AMD   77.10 (-0.68%)
T   19.10 (-0.93%)
MU   55.40 (-3.90%)
CGC   3.71 (+2.49%)
F   14.03 (+0.94%)
GE   85.44 (-0.62%)
DIS   97.78 (-0.09%)
AMC   8.57 (+18.53%)
PYPL   78.46 (+0.06%)
PFE   50.78 (+1.30%)
NFLX   316.52 (+3.60%)
S&P 500   4,073.51 (-0.16%)
DOW   34,344.96 (-0.71%)
QQQ   293.45 (+0.03%)
AAPL   148.12 (+0.06%)
MSFT   254.27 (-0.34%)
META   120.35 (+1.91%)
GOOGL   101.19 (+0.20%)
AMZN   95.59 (-0.98%)
TSLA   194.76 (+0.03%)
NVDA   172.08 (+1.68%)
NIO   12.28 (-3.91%)
BABA   86.13 (-1.63%)
AMD   77.10 (-0.68%)
T   19.10 (-0.93%)
MU   55.40 (-3.90%)
CGC   3.71 (+2.49%)
F   14.03 (+0.94%)
GE   85.44 (-0.62%)
DIS   97.78 (-0.09%)
AMC   8.57 (+18.53%)
PYPL   78.46 (+0.06%)
PFE   50.78 (+1.30%)
NFLX   316.52 (+3.60%)
S&P 500   4,073.51 (-0.16%)
DOW   34,344.96 (-0.71%)
QQQ   293.45 (+0.03%)
AAPL   148.12 (+0.06%)
MSFT   254.27 (-0.34%)
META   120.35 (+1.91%)
GOOGL   101.19 (+0.20%)
AMZN   95.59 (-0.98%)
TSLA   194.76 (+0.03%)
NVDA   172.08 (+1.68%)
NIO   12.28 (-3.91%)
BABA   86.13 (-1.63%)
AMD   77.10 (-0.68%)
T   19.10 (-0.93%)
MU   55.40 (-3.90%)
CGC   3.71 (+2.49%)
F   14.03 (+0.94%)
GE   85.44 (-0.62%)
DIS   97.78 (-0.09%)
AMC   8.57 (+18.53%)
PYPL   78.46 (+0.06%)
PFE   50.78 (+1.30%)
NFLX   316.52 (+3.60%)
NASDAQ:GENE

Genetic Technologies - GENE Stock Forecast, Price & News

$1.11
-0.03 (-2.63%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.08
$1.13
50-Day Range
$1.08
$1.35
52-Week Range
$0.95
$2.85
Volume
60,424 shs
Average Volume
15,761 shs
Market Capitalization
$17.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GENE stock logo

About Genetic Technologies (NASDAQ:GENE) Stock

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GENE Stock News Headlines

What 5 Analyst Ratings Have To Say About Applied Genetic Techs
Expert Ratings for Applied Genetic
See More Headlines
Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GENE Company Calendar

Today
12/01/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GENE
Employees
18
Year Founded
1989

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.86 million
Book Value
$0.77 per share

Miscellaneous

Free Float
14,396,000
Market Cap
$17.08 million
Optionable
Optionable
Beta
2.00

Social Links


Key Executives

  • Mr. Simon Morriss
    Chief Exec. Officer
  • Dr. Richard Allman Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $150.32k
  • Mr. Carl S. Stubbings BSc
    Chief Commercial Officer
  • Mr. Tony Di Pietro AGIA
    B.Com, C.A., CPA, M.A.I.C.D., CFO & Company Sec.
  • Mr. Paul Keith Mathieson Viney B. Bus
    FCI, FCPA, FGIA, Consultant
  • Mr. Kevin Camilleri
    Chief Exec. Officer of EasyDNA













GENE Stock - Frequently Asked Questions

How have GENE shares performed in 2022?

Genetic Technologies' stock was trading at $1.88 at the beginning of the year. Since then, GENE stock has decreased by 41.0% and is now trading at $1.11.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Genetic Technologies own?
What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

Who are Genetic Technologies' major shareholders?

Genetic Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include OLD Mission Capital LLC (0.22%) and Continental Investors Services Inc. (0.21%).

How do I buy shares of Genetic Technologies?

Shares of GENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $1.11.

How much money does Genetic Technologies make?

Genetic Technologies (NASDAQ:GENE) has a market capitalization of $17.08 million and generates $4.86 million in revenue each year.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The official website for the company is www.gtgcorporate.com. The biotechnology company can be reached via phone at (138) 412-7000, via email at ir@gtgcorporate.com, or via fax at 011-61-3-8412-7040.

This page (NASDAQ:GENE) was last updated on 12/1/2022 by MarketBeat.com Staff